<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426257</url>
  </required_header>
  <id_info>
    <org_study_id>M06OVH-OVHIPEC</org_study_id>
    <secondary_id>2006-003466-34</secondary_id>
    <secondary_id>2006-16</secondary_id>
    <nct_id>NCT00426257</nct_id>
  </id_info>
  <brief_title>Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer</brief_title>
  <official_title>Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of the addition of hyperthermic intraperitoneal
      chemotherapy to secondary debulking surgery in stage III ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Ovarian cancer is the second most common gynaecologic cancer in the Netherlands
      preceded by endometrial cancer. It is however the leading cause of death among women with
      gynaecologic malignancies with an annual mortality rate of 9 per 100.000. The majority of the
      patients are diagnosed with a high stage ovarian carcinoma due to the fact that symptoms
      occur at a late stage of the disease and screening methods for ovarian cancer are suboptimal.
      Optimal treatment consists of a combination of chemotherapy and debulking surgery. Despite
      the appearance of localized disease and the absence of obvious residual tumour following
      primary treatment, the majority of patients (80%) will have persistent disease or will
      develop recurrent disease. Additional strategies are warranted to reduce the recurrence rate
      and increase disease free survival and overall survival in this group of patients.

      The concept of administering intraperitoneal chemotherapy is based on the ideas on peritoneal
      dialysis. Intraperitoneal drug therapy is designed to maximize drug delivery to the tumour
      with generally acceptable systemic side effects associated with IV administration of the
      drug. This strategy is especially attractive for treatment of ovarian carcinoma, which
      remains largely restricted to the abdominal cavity for most of its natural history. So far 3
      randomised controlled trials have shown an overall and progression-free survival benefit when
      cisplatin is administered postoperatively by the IP route in patients with stage III,
      optimally resected disease. These studies however found that the majority of patients did not
      complete all planned 6 cycles due to catheter related problems. An alternative way of
      administering chemotherapy intra abdominally whilst bypassing the use of a catheter intra-
      abdominally is provided by perfusion of the abdomen during surgery under hyperthermic
      conditions. This study compares the interval debulking plus or minus the perfusion of the
      abdomen with chemotherapy under hyperthermic conditions during surgery (OVHIPEC).

      Objective: The primary objectives of this study are comparing the duration of recurrence free
      survival following completion of treatment between the 2 study arms.

      Secondary objectives of this study involve toxicity and morbidity, quality of life, tumour
      response following treatment and overall survival of the study arm compared to the standard
      arm.

      Study design: Phase III randomised trial Study population: Patients diagnosed with stage III
      ovarian carcinoma, peritoneal cell carcinoma or tuba carcinoma who are eligible for interval
      debulking surgery either following primary chemotherapy or following incomplete primary
      debulking and chemotherapy. Age between 18 - 76 yr old.

      Intervention: One group undergoes interval debulking with hyperthermic perfusion of the
      abdominal cavity with cisplatin 100 mg/m2 at the end of surgery. The other group is treated
      by interval debulking only.

      Main study parameters/endpoints: Recurrence free survival Nature and extent of the burden and
      risks associated with participation, benefit and group relatedness: Participants of the study
      will be asked to fill in quality of life questionnaires (12 times in 2 year). Blood samples
      will be taken following written informed consent before treatment, during surgery and during
      follow-up visits for marker studies and proteomics studies (10 times during 2 year). For
      patients participating in the pharmacokinetic studies (20) 2 tissue samples will be taken
      from the abdominal cavity during surgery and blood samples will be taken 6 times during and
      after surgery.

      During follow-up 3 monthly visits will be scheduled in the first 2 years and 6-monthly visits
      during year 3-5. During these follow-up visits routine physical exam including pelvic exam
      and vaginal ultrasound (optional) is performed. CT-scans will be performed in the first 2
      years before randomisation and 4 times at follow-up.

      Risks of participating in this trial are related to the abdominal perfusion of cisplatin.
      This can cause systemic effects such as: nephrotoxicity, bone marrow toxicity, neurotoxicity,
      and longer hospital stay. It can also increase the chance on bowel perforation of a bowel
      anastomoses resulting in a longer hospital stay and possibly surgical intervention. To
      prevent systemic side effects of intra-abdominally administered cisplatin, sodium
      thiosulphate is administered intravenously during surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 16, 2017</completion_date>
  <primary_completion_date type="Actual">August 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of recurrence free survival.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity and morbidity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Secondary debulking surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Secondary debulking</intervention_name>
    <description>Secondary debulking</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>secondary debulking with intraperitoneal chemotherapy</intervention_name>
    <description>secondary debulking with intraperitoneal chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 76 years

          -  Histological or cytological proven primary epithelial ovarian carcinoma or peritoneal
             cancer (PPSC) or fallopian tube carcinoma FIGO stage III, including serous papillary
             adenocarcinoma, mucinous adenocarcinoma and endometrioid adenocarcinoma.

          -  In case of pleural effusion cytology should be negative for tumour cells

          -  In case diagnosis is made based on cytology only (i.e. patients treated by primary
             chemotherapy) additional criteria apply:

               -  Normal mammogram (&lt; 6 weeks before first registration) and

               -  Presence of pelvic mass and

               -  CA 125 &gt; 200 kU/l and

               -  Serum CA125/CEA ratio &gt; 25. If the serum CA125/CEA ratio is &lt; 25, a barium enema
                  or colonoscopy and gastroscopy or radiological examination of the stomach should
                  be negative for the presence of a primary tumour of the digeste tract (&lt; 6 weeks
                  before registration) and

               -  Omental cake or other metastases larger than 2 cm in the upper abdomen and/or
                  regional lymph node metastasis irrespective of size (CT/MRI or ultrasound or
                  laparoscopy)

          -  Patients eligible for interval debulking for the following 2 reasons:

               -  Primary debulking surgery not feasible due to tumour extension or general
                  condition (patients treated by primary chemotherapy) or

               -  Incomplete primary debulking with residual disease &gt; 1 cm

          -  In case of primary chemotherapy:

               -  Chemotherapy consists of 3 courses of carboplatin or cisplatin combined with
                  taxol

               -  Following 2 cycles of chemotherapy at least a 30% decrease in the sum of largest
                  diameter (LD) of target lesions taking as reference the baseline sum LD (RECIST
                  criteria, see appendix 1)

          -  In case of an incomplete primary debulking as indicated under 5 followed by
             chemotherapy:

               -  Chemotherapy consists of 3 courses of carboplatin or cisplatin combined with
                  taxol

          -  General criteria:

               -  Fit for major surgery, ASA 1 or ASA 2

               -  WHO performance status 0-2

               -  Written informed consent

               -  Laboratory values: serum creatinine &lt; 140 Âµmol/L; creatinine clearance &gt; 60
                  ml/min (Cockroft formula); white blood cell count &gt; 3.5 x 109/l; platelets &gt; 100
                  x 109 /l

          -  For quality of life studies:

               -  Baseline questionnaires should be filled in before randomization

        Exclusion Criteria:

          -  History of breast cancer or previous malignancies within 5 years prior to inclusion,
             with the exception of radically excised basal cell or squamous cell skin cancer or
             carcinoma in situ of the cervix
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willemien J van Driel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>stage III</keyword>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>debulking surgery</keyword>
  <keyword>HIPEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

